<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34310172</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1527-7755</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>39</Volume>
            <Issue>31</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Nov</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title>
          <ISOAbbreviation>J Clin Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.</ArticleTitle>
        <Pagination>
          <StartPage>3441</StartPage>
          <EndPage>3452</EndPage>
          <MedlinePgn>3441-3452</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.21.01210</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE">Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We conducted an open-label, randomized, noninferiority, phase III trial comparing acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia (CLL).</AbstractText>
          <AbstractText Label="METHODS">Patients with previously treated CLL with centrally confirmed del(17)(p13.1) or del(11)(q22.3) were randomly assigned to oral acalabrutinib 100 mg twice daily or ibrutinib 420 mg once daily until progression or unacceptable toxicity. The primary end point was independent review committee-assessed noninferiority of progression-free survival (PFS).</AbstractText>
          <AbstractText Label="RESULTS">Overall, 533 patients (acalabrutinib, n = 268; ibrutinib, n = 265) were randomly assigned. At the data cutoff, 124 (46.3%) acalabrutinib patients and 109 (41.1%) ibrutinib patients remained on treatment. After a median follow-up of 40.9 months, acalabrutinib was determined to be noninferior to ibrutinib with a median PFS of 38.4 months in both arms (95% CI acalabrutinib, 33.0 to 38.6 and ibrutinib, 33.0 to 41.6; hazard ratio: 1.00; 95% CI, 0.79 to 1.27). All-grade atrial fibrillation/atrial flutter incidence was significantly lower with acalabrutinib versus ibrutinib (9.4% <i>v</i> 16.0%; <i>P</i> = .02); among other selected secondary end points, grade 3 or higher infections (30.8% <i>v</i> 30.0%) and Richter transformations (3.8% <i>v</i> 4.9%) were comparable between groups and median overall survival was not reached in either arm (hazard ratio, 0.82; 95% CI, 0.59 to 1.15), with 63 (23.5%) deaths with acalabrutinib and 73 (27.5%) with ibrutinib. Treatment discontinuations because of adverse events occurred in 14.7% of acalabrutinib-treated patients and 21.3% of ibrutinib-treated patients.</AbstractText>
          <AbstractText Label="CONCLUSION">In this first direct comparison of less versus more selective Bruton's tyrosine kinase inhibitors in CLL, acalabrutinib demonstrated noninferior PFS with fewer cardiovascular adverse events.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Byrd</LastName>
            <ForeName>John C</ForeName>
            <Initials>JC</Initials>
            <Identifier Source="ORCID">0000-0001-9830-0711</Identifier>
            <AffiliationInfo>
              <Affiliation>The Ohio State University Comprehensive Cancer Center, Columbus, OH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hillmen</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0001-5617-4403</Identifier>
            <AffiliationInfo>
              <Affiliation>St James's University Hospital, Leeds, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ghia</LastName>
            <ForeName>Paolo</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0003-3750-7342</Identifier>
            <AffiliationInfo>
              <Affiliation>Università Vita-Salute San Raffaele, Milano, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>IRCCS Ospedale San Raffaele, Milano, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kater</LastName>
            <ForeName>Arnon P</ForeName>
            <Initials>AP</Initials>
            <Identifier Source="ORCID">0000-0003-3190-1891</Identifier>
            <AffiliationInfo>
              <Affiliation>Amsterdam University Medical Centers, University of Amsterdam, on behalf of Hovon, Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chanan-Khan</LastName>
            <ForeName>Asher</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Mayo Clinic Jacksonville, Jacksonville, FL.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Furman</LastName>
            <ForeName>Richard R</ForeName>
            <Initials>RR</Initials>
            <Identifier Source="ORCID">0000-0003-1677-7626</Identifier>
            <AffiliationInfo>
              <Affiliation>Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>O'Brien</LastName>
            <ForeName>Susan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Chao Family Comprehensive Cancer Center, University of California-Irvine, Irvine, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yenerel</LastName>
            <ForeName>Mustafa Nuri</ForeName>
            <Initials>MN</Initials>
            <Identifier Source="ORCID">0000-0002-6473-1342</Identifier>
            <AffiliationInfo>
              <Affiliation>Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Illés</LastName>
            <ForeName>Arpad</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>University of Debrecen, Debrecen, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kay</LastName>
            <ForeName>Neil</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0002-5951-5055</Identifier>
            <AffiliationInfo>
              <Affiliation>Mayo Clinic Rochester, Rochester, MN.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Garcia-Marco</LastName>
            <ForeName>Jose A</ForeName>
            <Initials>JA</Initials>
            <AffiliationInfo>
              <Affiliation>Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mato</LastName>
            <ForeName>Anthony</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0001-8724-1875</Identifier>
            <AffiliationInfo>
              <Affiliation>University of Pennsylvania, Philadelphia, PA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pinilla-Ibarz</LastName>
            <ForeName>Javier</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Moffitt Cancer Center, Tampa, FL.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Seymour</LastName>
            <ForeName>John F</ForeName>
            <Initials>JF</Initials>
            <Identifier Source="ORCID">0000-0003-2188-6835</Identifier>
            <AffiliationInfo>
              <Affiliation>Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lepretre</LastName>
            <ForeName>Stephane</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Centre Henri Becquerel, Rouen, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Normandie University UNIROUEN, Rouen, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stilgenbauer</LastName>
            <ForeName>Stephan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Internal Medicine III, University of Ulm, Ulm, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Robak</LastName>
            <ForeName>Tadeusz</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Medical University of Lodz, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rothbaum</LastName>
            <ForeName>Wayne</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta, South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Izumi</LastName>
            <ForeName>Raquel</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta, South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamdy</LastName>
            <ForeName>Ahmed</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta, South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Priti</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>AstraZeneca, South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Higgins</LastName>
            <ForeName>Kara</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>AstraZeneca, South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sohoni</LastName>
            <ForeName>Sophia</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>AstraZeneca, South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jurczak</LastName>
            <ForeName>Wojciech</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02477696</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R35 CA197734</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Clin Oncol</MedlineTA>
        <NlmUniqueID>8309333</NlmUniqueID>
        <ISSNLinking>0732-183X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010880">Piperidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1X70OSD4VX</RegistryNumber>
          <NameOfSubstance UI="C551803">ibrutinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I42748ELQW</RegistryNumber>
          <NameOfSubstance UI="C000604908">acalabrutinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>JAC85A2161</RegistryNumber>
          <NameOfSubstance UI="D000225">Adenine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>J Clin Oncol. 2021 Nov 1;39(31):3419-3422</RefSource>
          <PMID Version="1">34310198</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000225" MajorTopicYN="N">Adenine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015451" MajorTopicYN="N">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement><b>John C. Byrd</b><b>Stock and Other Ownership Interests:</b> Vincerx Pharma<b>Honoraria:</b> Pharmacyclics, AstraZeneca, Novartis, Syndax, Trillium Therapeutics<b>Consulting or Advisory Role:</b> Acerta Pharma, Janssen, Kura Oncology, Novartis, Syndax, AstraZeneca<b>Research Funding:</b> Acerta Pharma, Pharmacyclics, Zencor<b>Patents, Royalties, Other Intellectual Property:</b> OSU Patents<b>Travel, Accommodations, Expenses:</b> Gilead Sciences, Janssen, Novartis, Pharmacyclics, TG Therapeutics <b>Peter Hillmen</b><b>Honoraria:</b> Janssen, AbbVie, Roche<b>Research Funding:</b> Janssen, Pharmacyclics, Roche, Gilead Sciences, AbbVie<b>Travel, Accommodations, Expenses:</b> Janssen, AbbVie <b>Paolo Ghia</b><b>Honoraria:</b> AbbVie, BeiGene, Janssen Oncology, Gilead Sciences, Juno Therapeutics, Sunesis Pharmaceuticals, ArQule, Adaptive Biotechnologies, Dynamo Therapeutics, MEI Pharma, Acerta Pharma/AstraZeneca, Juno/Celgene/Bristol Myers Squibb, MSD, Lilly, Roche<b>Consulting or Advisory Role:</b> AbbVie, BeiGene, Janssen, Gilead Sciences, Sunesis Pharmaceuticals, Juno Therapeutics, ArQule, Adaptive Biotechnologies, Dynamo Therapeutics, MEI Pharma, Acerta Pharma/AstraZeneca, MSD, Lilly, Roche<b>Research Funding:</b> AbbVie, Janssen Oncology, Gilead Sciences, Sunesis Pharmaceuticals, Novartis, AstraZeneca <b>Arnon P. Kater</b><b>Consulting or Advisory Role:</b> Janssen Oncology, AbbVie/Genentech, AstraZeneca, Bristol Myers Squibb/Celgene, Lava Therapeutics<b>Research Funding:</b> Janssen Oncology, Roche/Genentech, Bristol Myers Squibb/Celgene, AbbVie, AstraZeneca<b>Travel, Accommodations, Expenses:</b> Acerta Pharma/AstraZeneca, Roche/Genentech <b>Asher Chanan-Khan</b><b>Stock and Other Ownership Interests:</b> Matthew &amp; Asher Inc, NanoDev Therapeutics, STARTON Therapeutics<b>Honoraria:</b> BeiGene, Ascentage Pharma<b>Research Funding:</b> Ascentage Pharma<b>Patents, Royalties, Other Intellectual Property:</b> Patent on PSMB9 biomarker <b>Richard R. Furman</b><b>Honoraria:</b> Janssen, AstraZeneca<b>Consulting or Advisory Role:</b> Pharmacyclics, Janssen Biotech, Genentech/Roche, Loxo, TG Therapeutics, Verastem, Acerta Pharma, AstraZeneca, Beigene, Incyte, OncoTracker, AbbVie, MorphoSys, Sanofi<b>Research Funding:</b> Acerta Pharma, TG Therapeutics<b>Expert Testimony:</b> AbbVie, Janssen Oncology<b>Travel, Accommodations, Expenses:</b> TG Therapeutics, Janssen Oncology<b>Other Relationship:</b> Incyte, Janssen Biotech <b>Susan O'Brien</b><b>Employment:</b> University of California, Irvine<b>Honoraria:</b> Celgene, Janssen, Pharmacyclics, Gilead Sciences, Pfizer, Amgen, Astellas Pharma, GlaxoSmithKline, Aptose Biosciences, Vaniam Group, AbbVie, Sunesis Pharmaceuticals, Alexion Pharmaceuticals, Eisai, TG Therapeutics, Nova Research Company<b>Consulting or Advisory Role:</b> Amgen, Celgene, GlaxoSmithKline, Janssen Oncology, Aptose Biosciences, Vaniam Group, AbbVie/Genentech, Sunesis Pharmaceuticals, Alexion Pharmaceuticals, Astellas Pharma, Gilead Sciences, Pharmacyclics, TG Therapeutics, Pfizer, Sunesis Pharmaceuticals<b>Research Funding:</b> Acerta Pharma, Regeneron, Gilead Sciences, Pfizer, TG Therapeutics, Pharmacyclics, Kite, a Gilead company, Sunesis Pharmaceuticals<b>Travel, Accommodations, Expenses:</b> Celgene, Janssen, Gilead Sciences, Regeneron, Janssen Oncology <b>Mustafa Nuri Yenerel</b><b>Consulting or Advisory Role:</b> Pfizer, Alexion Pharmaceuticals<b>Speakers' Bureau:</b> Janssen Oncology<b>Travel, Accommodations, Expenses:</b> Pfizer <b>Arpad Illés</b><b>Consulting or Advisory Role:</b> Janssen, Takeda, Novartis, Pfizer, Roche, Celgene<b>Research Funding:</b> Takeda, Seattle Genetics<b>Travel, Accommodations, Expenses:</b> Novartis, Janssen, Pfizer, Roche <b>Neil Kay</b><b>Consulting or Advisory Role:</b> MorphoSys, Celgene, Agios, CytomX Therapeutics, AstraZeneca, Pharmacyclics, DAVA Pharmaceuticals, Juno Therapeutics, Rigel, Oncotracker, Bristol Myers Squibb, AbbVie, Targeted Oncology, Acerta Pharma/AstraZeneca, MEI Pharma, Sunesis Pharmaceuticals, TG Therapeutics, Tolero Pharmaceuticals, Janssen Biotech, Genentech/AbbVie<b>Research Funding:</b> Pharmacyclics/Janssen, Tolero Pharmaceuticals, Acerta Pharma, MEI Pharma, Celgene, Genentech, Sunesis Pharmaceuticals, AbbVie, TG Therapeutics, Bristol Myers Squibb <b>Jose A. Garcia-Marco</b><b>Consulting or Advisory Role:</b> AbbVie, Janssen, AstraZeneca Spain<b>Speakers' Bureau:</b> AbbVie, Janssen, AstraZeneca Spain<b>Research Funding:</b> AbbVie, Janssen<b>Travel, Accommodations, Expenses:</b> AbbVie, Janssen <b>Anthony Mato</b><b>Consulting or Advisory Role:</b> TG Therapeutics, AbbVie/Genentech, Celgene, Pharmacyclics, Adaptive Biotechnologies, Verastem, Johnson &amp; Johnson, Acerta Pharma/AstraZeneca, DTRM, Loxo/Lilly, Curio/Vaniam Group, Merck, Bristol Myers Squibb/Pfizer<b>Research Funding:</b> Regeneron, TG Therapeutics, Sunesis Pharmaceuticals, LOXO, AbbVie/Genentech, Pharmacyclics, Adaptive Biotechnologies, Johnson &amp; Johnson, Acerta Pharma/AstraZeneca, DTRM, Genmab, Nurix <b>Javier Pinilla-Ibarz</b><b>Honoraria:</b> Novartis, Pharmacyclics, Janssen, AbbVie, Takeda, AstraZeneca<b>Consulting or Advisory Role:</b> Novartis, Pharmacyclics, Janssen, AbbVie<b>Speakers' Bureau:</b> Pharmacyclics/Janssen, AbbVie, Takeda, AstraZeneca<b>Patents, Royalties, Other Intellectual Property:</b> From a WT vaccine patent by Memorial Sloan Kettering Cancer Center <b>John F. Seymour</b><b>Honoraria:</b> AbbVie, Acerta Pharma, Janssen, Roche, Sunesis Pharmaceuticals, Takeda<b>Consulting or Advisory Role:</b> AbbVie, Acerta Pharma, Janssen, Roche, Sunesis Pharmaceuticals, Takeda, AstraZeneca, BMS, Gilead Sciences, MEI Pharma, MorphoSys<b>Speakers' Bureau:</b> AbbVie, Roche<b>Research Funding:</b> AbbVie, Celgene, Janssen, Roche<b>Expert Testimony:</b> Roche<b>Travel, Accommodations, Expenses:</b> AbbVie, Roche <b>Stephan Stilgenbauer</b><b>Honoraria:</b> AbbVie, AstraZeneca, Celgene, Gilead Sciences, GlaxoSmithKline, Roche, Janssen<b>Consulting or Advisory Role:</b> AbbVie, AstraZeneca, Celgene, Gilead Sciences, GlaxoSmithKline, Roche, Janssen<b>Speakers' Bureau:</b> AbbVie, AstraZeneca, Celgene, Gilead Sciences, GlaxoSmithKline, Roche, Janssen<b>Research Funding:</b> AbbVie, AstraZeneca, Celgene, Gilead Sciences, GlaxoSmithKline, Roche, Janssen<b>Travel, Accommodations, Expenses:</b> AbbVie, AstraZeneca, Celgene, Gilead Sciences, GlaxoSmithKline, Roche, Janssen <b>Tadeusz Robak</b><b>Honoraria:</b> AbbVie<b>Consulting or Advisory Role:</b> AbbVie<b>Research Funding:</b> AbbVie/Genentech <b>Wayne Rothbaum</b><b>Leadership:</b> Iovance Biotherapeutics<b>Stock and Other Ownership Interests:</b> Acerta Pharma/AstraZeneca, Telios, Kartos Therapeutics<b>Patents, Royalties, Other Intellectual Property:</b> Telios Pharma and Kartos Therapeutics<b>Travel, Accommodations, Expenses:</b> Iovance Biotherapeutics, Kartos Therapeutics<b>Uncompensated Relationships:</b> Kartos Therapeutics, Telios <b>Raquel Izumi</b><b>Employment:</b> Acerta Pharma, Vincerx Pharma<b>Stock and Other Ownership Interests:</b> Acerta Pharma, Vincerx Pharma<b>Patents, Royalties, Other Intellectual Property:</b> Patents pending for Acerta Pharma<b>Expert Testimony:</b> Diablo Valley Oncology <b>Ahmed Hamdy</b><b>Employment:</b> Acerta Pharma/AstraZeneca<b>Stock and Other Ownership Interests:</b> Acerta Pharma<b>Patents, Royalties, Other Intellectual Property:</b> Acalabrutinib multiple patents <b>Priti Patel</b><b>Employment:</b> AstraZeneca, Neoleukin Therapeutics<b>Leadership:</b> Neoleukin Therapeutics<b>Stock and Other Ownership Interests:</b> AstraZeneca, Neoleukin Therapeutics <b>Kara Higgins</b><b>Employment:</b> AstraZeneca, PROMETRIKA LLC <b>Sophia Sohoni</b><b>Employment:</b> AstraZeneca, Portola Pharmaceuticals<b>Stock and Other Ownership Interests:</b> Theravance <b>Wojciech Jurczak</b><b>Consulting or Advisory Role:</b> Janssen-Cilag, Roche, AstraZeneca, Debiopharm Group, Epizyme<b>Research Funding:</b> Acerta Pharma, TG Therapeutics, Incyte, Bayer, Sandoz-Novartis, Roche, Takeda, Epizyme, Janssen-Cilag, BeiGene, Debiopharm Group, MorphoSys, MEI PharmaNo other potential conflicts of interest were reported.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>26</Day>
          <Hour>17</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34310172</ArticleId>
        <ArticleId IdType="pmc">PMC8547923</ArticleId>
        <ArticleId IdType="doi">10.1200/JCO.21.01210</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Wen T, Wang J, Shi Y, et al. : Inhibitors targeting Bruton's tyrosine kinase in cancers: Drug development advances. Leukemia
35:312-332, 2021</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7862069</ArticleId>
            <ArticleId IdType="pubmed">33122850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kil LP, de Bruijn MJ, van Hulst JA, et al. : Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. Am J Blood Res
3:71-83, 2013</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3555194</ArticleId>
            <ArticleId IdType="pubmed">23359016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Rooij MF, Kuil A, Geest CR, et al. : The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood
119:2590-2594, 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22279054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger JA, Tedeschi A, Barr PM, et al. : Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med
373:2425-2437, 2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4722809</ArticleId>
            <ArticleId IdType="pubmed">26639149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Brown JR, O'Brien S, et al. : Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med
371:213-223, 2014</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4134521</ArticleId>
            <ArticleId IdType="pubmed">24881631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghia P, Pluta A, Wach M, et al. : ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol
38:2849-2861, 2020</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32459600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharman JP, Egyed M, Jurczak W, et al. : Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial. Lancet
395:1278-1291, 2020</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8151619</ArticleId>
            <ArticleId IdType="pubmed">32305093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barf T, Covey T, Izumi R, et al. : Acalabrutinib (ACP-196): A covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther
363:240-252, 2017</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28882879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imbruvica [package insert]. Sunnyvale, CA; Horsham, PA, Pharmacyclics; Janssen Biotech, 2020</Citation>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Hillmen P, O'Brien S, et al. : Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood
133:2031-2042, 2019</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6509542</ArticleId>
            <ArticleId IdType="pubmed">30842083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger JA, Barr PM, Robak T, et al. : Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia
34:787-798, 2020</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7214263</ArticleId>
            <ArticleId IdType="pubmed">31628428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caldeira D, Alves D, Costa J, et al. : Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis. PLoS One
14:e0211228, 2019</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6382095</ArticleId>
            <ArticleId IdType="pubmed">30785921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McMullen JR, Boey EJ, Ooi JY, et al. : Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood
124:3829-3830, 2014</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25498454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao L, Salem JE, Clauss S, et al. : Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase. Circulation
142:2443-2455, 2020</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33092403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salem JE, Manouchehri A, Bretagne M, et al. : Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol
74:1667-1678, 2019</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31558250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J, Kinoshita T, Sukbuntherng J, et al. : Ibrutinib inhibits ERBB receptor tyrosine kinases and HER2-amplified breast cancer cell growth. Mol Cancer Ther
15:2835-2844, 2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27678331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Harrington B, O'Brien S, et al. : Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med
374:323-332, 2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4862586</ArticleId>
            <ArticleId IdType="pubmed">26641137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bond DA, Woyach JA: Targeting BTK in CLL: Beyond ibrutinib. Curr Hematol Malig Rep
14:197-205, 2019</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31028669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel V, Balakrishnan K, Bibikova E, et al. : Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. Clin Cancer Res
23:3734-3743, 2017</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5491371</ArticleId>
            <ArticleId IdType="pubmed">28034907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caron F, Leong DP, Hillis C, et al. : Current understanding of bleeding with ibrutinib use: A systematic review and meta-analysis. Blood Adv
1:772-778, 2017</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5728050</ArticleId>
            <ArticleId IdType="pubmed">29296721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calquence [package insert]. Wilmington, DE, AstraZeneca Pharmaceuticals, 2019</Citation>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Woyach JA, Furman RR, et al. : Acalabrutinib in treatment-naïve chronic lymphocytic leukemia. Blood
137:3327-3328, 2021</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33786588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Wierda WG, Schuh A, et al. : Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: Updated phase 2 results. Blood
135:1204-1213, 2020</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7146022</ArticleId>
            <ArticleId IdType="pubmed">31876911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Awan FT, Schuh A, Brown JR, et al. : Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv
3:1553-1562, 2019</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6517672</ArticleId>
            <ArticleId IdType="pubmed">31088809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hallek M, Cheson BD, Catovsky D, et al. : Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood
111:5446-5456, 2008</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2972576</ArticleId>
            <ArticleId IdType="pubmed">18216293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Non-inferiority Clinical Trials to Establish Effectiveness. Guidance for Industry. Silver Spring, MD, US Department of Health and Human Services; Food and Drug Administration, 2016</Citation>
        </Reference>
        <Reference>
          <Citation>Eichhorst B, Goede V, Hallek M: Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma
50:171-178, 2009</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19197731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown JR, Moslehi J, O'Brien S, et al. : Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica
102:1796-1805, 2017</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5622864</ArticleId>
            <ArticleId IdType="pubmed">28751558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiczer TE, Levine LB, Brumbaugh J, et al. : Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv
1:1739-1748, 2017</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5728342</ArticleId>
            <ArticleId IdType="pubmed">29296820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mato AR, Nabhan C, Barr PM, et al. : Outcomes of CLL patients treated with sequential kinase inhibitor therapy: A real world experience. Blood
128:2199-2205, 2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27601462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benjamin EJ, Wolf PA, D'Agostino RB, et al. : Impact of atrial fibrillation on the risk of death: The Framingham heart study. Circulation
98:946-952, 1998</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9737513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chai KL, Rowan G, Seymour JF, et al. : Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib. Leuk Lymphoma
58:2811-2814, 2017</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28504030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tam CS, Opat S, D'Sa S, et al. : A randomized phase 3 trial of zanubrutinib versus ibrutinib in symptomatic Waldenström macroglobulinemia:the ASPEN study. Blood
136:2038-2050, 2020</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7596850</ArticleId>
            <ArticleId IdType="pubmed">32731259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dickerson T, Wiczer T, Waller A, et al. : Hypertension and incident cardiovascular events following ibrutinib initiation. Blood
134:1919-1928, 2019</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6887116</ArticleId>
            <ArticleId IdType="pubmed">31582362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Comprehensive Cancer Network : NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 3.2021. Plymouth Meeting, PA, National Comprehensive Cancer Network, 2021</Citation>
        </Reference>
        <Reference>
          <Citation>Kipps TJ, Fraser G, Coutre SE, et al. : Long-term studies assessing outcomes of ibrutinib therapy in patients with del(11q) chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk
19:715-722.e6, 2019</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31447270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Brien S, Furman RR, Coutre S, et al. : Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: A 5-year experience. Blood
131:1910-1919, 2018</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5921964</ArticleId>
            <ArticleId IdType="pubmed">29437592</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
